Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet

Table 2 Anticipated population gains and losses - cases of the condition prevented or caused if all children currently unvaccinated were vaccinated^a.

Condition	Expected gain (number prevented) under original assumptions	Expected gain (number prevented) applying efficacy rates from Lasbela baseline survey^b
Diarrhoea	277 per thousand	30 per thousand
Bronchopneumonia	61 per thousand	7 per thousand
Blindness	27 per thousand	3 per thousand
Otitis media	25 per thousand	3 per thousand
Death	14 per thousand	15 per ten thousand
Convulsions	3 per thousand	3 per ten thousand
Post-infectious	4 per ten thousand	5 per hundred thousand
encephalitis	7 per million	7 per ten million
SSPE	Losses (original assumptions)	Losses after baseline survey
Anaphylaxis	7 per ten million	7 per hundred million

^a Sources for all calculations are the same as in Table 1. Differences in gains are due to revised assumptions following the baseline survey.
^b Gain = [RDx(PRIxVER)] × 0.361, where RD = Risk difference, PRI = proportion requiring intervention (0.49), and VER = Vaccine efficacy rate (0.415).
The bold-font rows show the conditions for which the data are most applicable to the South Asia region or, at least, developing country conditions - diarrhoea, pneumonia, blindness and death.

ISSN: 1472-698X